ArticleOncotarget2017

Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.

Min-Jie Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.